Phase 2 Multiple Myeloma in Relapse Clinical Trials
11 recruitingPhase 2
What is a Phase 2 trial?
Phase 2 trials evaluate whether a treatment works for a specific condition and further assess its safety. These studies typically enroll several hundred participants and provide preliminary data on effectiveness.
Showing 1–11 of 11 trials
Recruiting
Phase 2
Subcutaneous Talquetamab in Elderly Patients With Multiple Myeloma in Early Relapse
Multiple Myeloma in Relapse
Larysa Sanchez23 enrolled1 locationNCT06827860
Recruiting
Phase 2
Daratumumab, Carfilzomib, Pomalidomide, Dexamethasone In MM
Multiple MyelomaRelapseMultiple Myeloma in Relapse+1 more
Andrew Yee, MD43 enrolled3 locationsNCT04176718
Recruiting
Phase 2
HCMT/MM2401: Ph2 Study of Selinexor + Bispecific Antibody for RRMM
Multiple Myeloma in RelapseMultiple Myeloma, Refractory
Duke University27 enrolled1 locationNCT06822972
Recruiting
Phase 1Phase 2
Sequential CAR-T Cells Targeting BCMA/GPRC5D in Patients With Relapsed/ Refractory Multiple Myeloma
Multiple MyelomaMultiple Myeloma in RelapseMultiple Myeloma, Refractory+1 more
Essen Biotech60 enrolled1 locationNCT07032129
Recruiting
Phase 1Phase 2
Combination Treatment of Belantamab Mafodotin and Venetoclax in Treatment of Relapsed and Refractory T(11;14) Multiple Myeloma
Multiple MyelomaMultiple Myeloma in Relapse
Universitätsklinikum Hamburg-Eppendorf45 enrolled5 locationsNCT05853965
Recruiting
Phase 1Phase 2
a Clinical Research of BCMA-Targeted Prime CAR-T Cell Therapy in Relapsed/Refractory Multiple Myeloma and Plasma Cell Disease
Multiple MyelomaMultiple Myeloma in RelapseNeoplasm, Plasma Cell
Chongqing Precision Biotech Co., Ltd80 enrolled1 locationNCT04776330
Recruiting
Phase 1Phase 2
BCMA-Targeted CAR-T Cell Therapy for Relapsed/Refractory Multiple Myeloma and Plasma Cell Disease
Multiple MyelomaMultiple Myeloma in RelapseNeoplasm, Plasma Cell
Chongqing Precision Biotech Co., Ltd80 enrolled1 locationNCT04271644
Recruiting
Phase 2
All-trans Retinoic Acid in Combination With a KPD Regimen for the Treatment of Refractory/Relapsed Multiple Myeloma
Multiple Myeloma in RelapseMultiple Myeloma, Refractory
The First Affiliated Hospital of Xiamen University25 enrolled1 locationNCT06158412
Recruiting
Phase 2
A Study of Venetoclax in Combination With Isatuximab and Dexamethasone for Relapsed/Refractory Multiple Myeloma
Multiple Myeloma in RelapseMultiple Myeloma, Refractory
Oncotherapeutics39 enrolled2 locationsNCT06115135
Recruiting
Phase 1Phase 2
BCMA-GPRC5D CAR-T Therapy in Relapsed or Refractory Multiple Myeloma
Multiple Myeloma in Relapse
Shenzhen University General Hospital10 enrolled1 locationNCT06644443
Recruiting
Phase 2
Study of Elranatamab for Relapsed or Refractory Myeloma in Patients Previously Exposed to Three-drug Classes
Multiple Myeloma in Relapse
PETHEMA Foundation50 enrolled15 locationsNCT06282978